TCRX

MKT CAP:$64M

Tscan Therapeutics Inc

Market Cap

$64M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.98-$0.04 (-3.73%)

Jun 5, 2026

52W High $2.5252W Low $0.90

Company Details

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the tr...

CEO

—

IPO Date

Jul 16, 2021

Website

www.tscan.com

Key Metrics TTM

Revenue

$9M

+106.7% YoY

Net Income

-$124M

EPS (Diluted)

Free Cash Flow

-$125M

Revenue / Share

$0.07

Gross Margin

92.4%

Operating Margin

-1408.7%

Net Margin

-1360.6%

FCF Margin

-1367.7%

P/S

7.0x

P/E

Earnings Reports

Q1 2026

May 6, 2026

$982.0K-54.8%

FY 2025

Mar 4, 2026

$10M+266.7%

Q4 2025

Mar 4, 2026

$3M+286.0%

Q3 2025

Nov 12, 2025

$3M+139.4%

Q2 2025

Aug 12, 2025

$3M+473.9%

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee